Sorafenib for Metastatic Renal Cancer
- 1 April 2008
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in American Journal of Clinical Oncology
- Vol. 31 (2), 182-187
- https://doi.org/10.1097/coc.0b013e3181574084
Abstract
Sorafenib, an oral multikinase inhibitor, prolonged progression-free survival when compared with placebo, as second-line therapy for patients with metastatic renal carcinoma (MRC). Grade 3/4 adverse events were reported in 12% of patients. This study presents sorafenib's efficacy and safety in a less selected cohort of patients enrolled in an expanded access program. Patients with MRC received sorafenib 400 mg twice daily until disease progression. Tumor response was evaluated by RECIST criteria. Adverse events were graded by NCI common toxicity criteria. From November 2005 to August 2006, 58 patients were enrolled. The median progression-free survival was 7.5 months (95% CI: 5.4–11.3), and the best responses among 54 patients were 11 (20%) confirmed partial responses, 15 (28%) stable diseases for ≥6 months; 10 patients (18%) had early progression at 8 weeks. Grade 3/4 adverse events occurred in 37 patients (64%; 95% CI: 50%–76%), the most frequent being skin rash in 17 patients (29%), and hand-foot syndrome in 9 patients (15%). Thirty-six (62%) patients required dose reductions and/or treatment interruptions. Sorafenib is effective in a less selected patient population with MRC but leads to more toxicity than described previously.Keywords
This publication has 17 references indexed in Scilit:
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Renal-Cell CarcinomaNew England Journal of Medicine, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Cancer, 2004
- Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- Renal Cell Carcinoma: A Priority Malignancy for Development and Study of Novel TherapiesJournal of Clinical Oncology, 2003
- The von Hippel–Lindau tumor suppressor protein: new insights into oxygen sensing and cancerCurrent Opinion in Genetics & Development, 2002
- Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parametersGenes, Chromosomes and Cancer, 2002